title: [The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction].
abstract: OBJECTIVE
  To assess antiischemic efficacy, safety and effect on myocardial perfusion of a course treatment with mildronate (as monotherapy and in combination with atenolol) in patients with postinfarction left ventricular dysfunction associated with moderate heart failure.
  
  
  METHODS
  Patients (n=47) with postinfarction cardiosclerosis, angina, and decreased tolerance to physical exertion were divided into 2 groups. Patients of group 1 had functional class II angina and NYHA class I-II heart failure, patients of group 2 had functional class II-III angina and severe heart failure. Mildronate (0.75-1.0 g/day) was used as monotherapy in group 1 and in combination with atenolol (25-50 mg/day) in group 2. Duration of therapy was 3 weeks.
  
  
  CONCLUSIONS
  The use of mildronate was associated with marked antiischemic effect. Combined administration of mildronate and atenolol resulted in additional antiischemic effect without impairment of hemodynamics in patients with severe heart failure. Course use of mildronate was well tolerated. Adverse effects were registered in 4,2% of cases.
authors.affiliation: Research Institute for Cardiology of the Research Centre of RAMS Siberian Branch; ul. Kievskaya 111, 634012 Tomsk, Russia.
authors.forename: A T
authors.initials: AT
authors.lastname: Teplyakov
authors.forename: T V
authors.initials: TV
authors.lastname: Sankevitch
authors.forename: T A
authors.initials: TA
authors.lastname: Stepatcheva
authors.forename: S E
authors.initials: SE
authors.lastname: Mamchur
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D001262:Atenolol / Q000008:administration & dosage / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008763:Methylhydrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D063991:Mitochondrial Trifunctional Protein; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors*; D009203:Myocardial Infarction / Q000150:complications*; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D000319:Adrenergic beta-Antagonists; D002317:Cardiovascular Agents; D008763:Methylhydrazines; D009097:Multienzyme Complexes; D001262:Atenolol; C050147:3-(2,2,2-trimethylhydrazine)propionate; D063991:Mitochondrial Trifunctional Protein